Welcome! For price inquiries, please feel free to contact us through the form on the right side. We will get back to you as soon as possible.
During the past decades, Creative Biostructure has established an unparalleled VLPs technology platform and focused on VLPs application with an expanding spectrum. Our VLPs platform has become a broadly and commonly applied technology, especially for vaccinology development, faciliating biomedicine research significantly.
Figure 1. Influenza virus particle showing the surface peptides of greatest interest in current influenza vaccine research. (Biotechnology and Bioengineering, 2012)
VLPs are based on the self-assembly of viral structural proteins, which can be expressed in various cell systems and contain native epitopes. As subunit vaccines, VLPs are unable to spread virus infection because lack of viral genome. Furthermore, VLPs are capable of stimulating immune responses efficiently.
Creative Biostructure can design and develop custom VLPs to deliver antigens to the immune system with both arms of the adaptive immunity. Our virus-like particle products are able to present antigenic epitopes in their proper conformation to induce humoral responses as a result. For example, we have produced customized influenza VLPs for preclinical trials, which can not only induce humoral and cellular immune responses but also reduce the antigen doses.
Creative Biostructure is expertized in VLPs vaccine formulation and innovation. We have used the most commonly applied adjuvan aluminum salts in our VLP-based vaccines formulation, enhancing the antigen immunogenicity remarkablely; while we have used excipients for various purposes such as reduction of VLPs aggregation and preservative. Creative Biostructure has made great efforts in innovative formulation development of VLP-based vaccines including:Reducing the dosage,
Mempro™ Virus-like Particles (VLPs) platform allows great variety of VLP-based vaccine production in various expression systems for a broad range of targets such as HPV, HBV, HIV, and Influenza virus. A major challenge in VLP-based vaccines development is that we need to remove the samples frequently in fermentation, following by the processes such as cell centrifugation, cell lysis, and purification of VLPs. In order to solve this problem, Creative Biostructure has developed a high-throughput platform which can perform laboratory/manufactural scale VLPs production with high yield and purity. Therefore, Mempro™ Virus-like Particles (VLPs) platform has a bright future in design of stimulating cellular immunity as biologics.
We also offer diverse Mempro™ Virus-like Particles (VLPs) Application services in different fields such as cell targeting, bioimaging, delivery systems, and lipoparticle technology, etc. Please feel free to contact us for a detailed quote.
P. Lagoutte, et al. (2016). Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli. Journal of Virological Methods,232: 8–11.
G. P. Pijlman, et al. (2015). Enveloped virus-like particles as vaccines against pathogenic arboviruses. Biotechnol. J., 10, 659-670.
J. O. Josefsberg, et al. (2012). Vaccine Process Technology. Biotechnol. Bioeng.,109: 1443–1460.